Booth no: Za’abeel Hall Z6.C40 VibroSense presents new ultra sensitive systems for measuring diabetic and other neuropathies at Arab Health 2017
Easy to use devices provide early warning of diabetic foot ulcers (DFU) and chemotherapy-induced peripheral neuropathies (CIPN)
Swedish medical device company VibroSense today showed its range of ultra-sensitive systems at Arab Health 2017. Already widely used in the construction, mining and other industries for diagnosing occupational health injuries, CE-marked VibroSense Meters are currently being introduced for a range of clinical applications. All systems utilize an innovative method called Multi-Frequency Vibrometry which provides an accurate measure of sensory perception in patient limbs. Two key initial applications have been identified as diabetic foot ulcers, and chemotherapy-induced peripheral neuropathies.
It is estimated that 10% of people with diabetes will have a diabetic ulcer at some point in their lives. Furthermore, such ulcers precede more than 80% of amputations in people with diabetes. The MENA countries have large numbers of DFU patients in particular relative to their populations; an example of this would be Saudi Arabia where a population circa 25m, may have more than 300,000 DFUs on any one day. VibroSense designed a special DFU system following a study showing a strong correlation between decreased sensory perception in patients’ feet and risk of foot ulcers.
“The VibroSense meter is compact and easy to use in the clinic, providing fast and accurate early detection of diabetic foot ulcers. We have found that there is a strong correlation between foot ulcers and impaired tactile sensation at low vibration frequencies,” says VibroSense Marketing Director Ulf Rogers. “We are also investigating the use of the meter for assessing and monitoring chemotherapy-induced peripheral neuropathy, which affects 30-90% of cancer patients. At Arab Health we look forward to meeting with potential partners in both these areas, as well as those working in occupational health.”
Toni Speidel, CEO, VibroSense Dynamics AB, 46 40 650 14 12, firstname.lastname@example.org, www.vibrosense.com
VibroSense Dynamics AB (public) develops and markets efficient systems for early detection and diagnosis of peripheral sensory neuropathy, i.e. disease of large nerve fibres and nerve trunks in the legs and arms.
The Company, founded in 2005, is listed on the Small Cap list AktieTorget since May 2015. The product portfolio includes a CE-marked medical device, the VibroSense Meter, for diagnostics of impaired sensitivity in the hands.